Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Accelerates Portfolio Shift After Pain-Drug Setback
![]() |
Vertex enters the coming months with momentum in cystic fibrosis franchises and an active pipeline, while a mid-stage pain trial failure forces a strategic pivot that can influence near-term commercial cadence. |









